ArticleBiologics : targets & therapy2009
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis.
Article in Biologics : targets & therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Potential drug development and therapeutic approaches for clinical intervention in COVID-19.Bioorganic chemistry · 2021Review
- Article
- Immune response biomarkers in human and veterinary research.Comparative immunology, microbiology and infectious diseases · 2018Review
- Increasing Enzyme Stability and Activity through Hydrogen Bond-Enhanced Halogen Bonds.Biochemistry · 2018Article
- Independent and interdependent immunoregulatory effects of IL-27, IFN-β, and IL-10 in the suppression of human Th17 cells and murine experimental autoimmune encephalomyelitis.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro™ 30G and BetacomfortPragmatic and observational research · 2013Article
- Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.The pharmacogenomics journal · 2012Review
- Cytokine control of inflammation and repair in the pathology of multiple sclerosis.The Yale journal of biology and medicine · 2012Review
- Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.Journal of neurology · 2012Article
- Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis.ACS chemical neuroscience · 2011Review
- Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.Current neuropharmacology · 2010Article
- Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis.Journal of inflammation research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents have changed the therapeutic approach to this disease. Interferon beta (IFNbeta)-1b represents the pioneer of those therapies. There is growing evidence from clinical trials on relapsing-remitting MS and clinically isolated syndromes suggestive of MS that IFNbeta-1b reduces the frequency and severity of relapses and the development of new and active brain lesions as assessed by magnetic resonance imaging. Long-term data suggest a persistent efficacy of IFNbeta-1b on disease activity and a positive effect in slowing disability worsening. Furthermore a reduction of relapse rate and a slight positive effect on the progression were demonstrated when IFNbeta-1b was administered to still-active secondary progressive MS. IFNbeta-1b therapy is well tolerated and relatively free of long-term side effects. In spite of the emergence of new agents for the treatment of MS, IFNbeta-1b still remains a first-line therapy with a fundamental role in all stages of the disease.
Indexed as
Identifiers
19707422PMC2726074What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.